Clinical Trial Update: Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study [Phase 1]

View source ↗

Summary

This document reports the withdrawal of a Phase 1 trial evaluating the combination of nivolumab and ipilimumab in pediatric and young adult patients with geneti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasm
• Constitutional Mismatch Repair Deficiency Syndrome
• Lymphoma
• Lynch Syndrome
• Malignant Solid Neoplasm
• Neuroblastoma
• Xeroderma Pigmentosum

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Status: WITHDRAWN